FDA recently issued warning letters to companies that manufacture and market over-the-counter products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylocococcus aureus.
FDA recently issued warning letters to companies that manufacture and market over-the-counter products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylocococcus aureus (MRSA).
“MRSA is a serious public health threat,” said Deborah Autor, director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research. “The FDA cannot allow companies to mislead consumers by making unproven prevention claims.”
Labels for some of the firms’ hand-sanitizing drug products also claim that they help prevent infection from Escherichia coli, H1N1 influenza virus, or both. FDA noted that it does not have sufficient evidence to demonstrate that these products are safe and effective for these purposes.
The FDA warning letters, which inform companies they are violating federal law, were sent to the following:
These companies have 15 days to correct the violations cited in the letters. Failure to do so may result in legal action, including seizure and injunction.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen